ArticleNature2026
Integrated signatures define mutational processes in prostate cancer.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
60 authors.
Andreas J Gruber *Department of Biology, University of Konstanz, Konstanz, Germany.ORCID http://orcid.org/0000-0001-7664-4257
André V Olsen *Biotech Research & Innovation Centre (BRIC) - University of Copenhagen, Copenhagen, Denmark.
Barbara Hernando *Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0003-4019-2732
Kevin C L Cheng *Computational Biology Program, Ontario Institute for Cancer Research (OICR), Toronto, Ontario, Canada.
Clarissa GerhäuserDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5792-3901
Marina TorresSpanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0003-0272-9922
Francesco FaveroBiotech Research & Innovation Centre (BRIC) - University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-3684-2659
Daria KiriyBiotech Research & Innovation Centre (BRIC) - University of Copenhagen, Copenhagen, Denmark.
Ángel Fernández-SanrománSpanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0002-5851-9441
Juan Maria Roldan-RomeroSpanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0002-5651-4313
Lucy BartonManchester Cancer Research Centre and Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0003-2805-1160
Diogo PellegrinaComputational Biology Program, Ontario Institute for Cancer Research (OICR), Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-6423-5093
G Steven BovaProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Daniel S BrewerNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.ORCID http://orcid.org/0000-0003-4753-9794
Mark N BrookThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-8969-2378
Benedikt BrorsDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5940-3101
Adam ButlerWellcome Sanger Institute, Hinxton, UK.
Géraldine Cancel-TassinCeRePP (Centre de Recherche sur les Pathologies Prostatiques et Urologiques), Paris, France.ORCID http://orcid.org/0000-0002-9583-6382
Niall M CorcoranCollaborative Centre for Genomic Cancer Medicine, The Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0003-4483-6945
Olivier CussenotCeRePP (Centre de Recherche sur les Pathologies Prostatiques et Urologiques), Paris, France.
Abraham GihawiNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.ORCID http://orcid.org/0000-0002-3676-5561
Etsehiwot G GirmaBiotech Research & Innovation Centre (BRIC) - University of Copenhagen, Copenhagen, Denmark.
Vincent J GnanapragasamDepartment of Surgery, University of Cambridge, Cambridge, UK.
Anis A HamidDepartment of Surgery, The University of Melbourne, Parkville, Victoria, Australia.
Vanessa M HayesManchester Cancer Research Centre and Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-4524-7280
Housheng Hansen HeDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Christopher M HovensCollaborative Centre for Genomic Cancer Medicine, The Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0002-0610-1289
Eddie L ImadaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
G Maria JakobsdottirDivision of Cancer Sciences, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0001-8225-6541
Chol-Hee JungMelbourne Bioinformatics, The University of Melbourne, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0002-2992-3162
Francesca KhaniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-7238-8604
Zsofia Kote-JaraiThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-6329-5155
Philippe LamyDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-1347-7724
Gregory LeemanWellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0001-5212-6850
Massimo LodaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-9674-8379
Pavlo LutsikDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Luigi MarchionniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-7336-8071
Ramyar MolaniaWalter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Anthony T PapenfussWalter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0002-1102-8506
Bernard PopeDepartment of Surgery, The University of Melbourne, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0002-4840-1095
Lucio R QueirozDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-6090-1834
Tobias RauschGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5773-5620
Brian RobinsonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-5374-890X
Atef SahliManchester Cancer Research Centre and Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Karina D SørensenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID http://orcid.org/0000-0002-4902-5490
Takafumi N YamaguchiJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-1082-3871
Sebastian UhrigDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Yaobo XuWellcome Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0003-1242-513X
Claudio ZanettiniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Pan Prostate Cancer Group (PPCG)
Ronald SimonInstitute of Pathology, University Medical Centre Hamburg - Eppendorf (UKE), Hamburg, Germany.ORCID http://orcid.org/0000-0003-0158-4258
Guido SauterInstitute of Pathology, University Medical Centre Hamburg - Eppendorf (UKE), Hamburg, Germany.
Ros A EelesThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-3698-6241
Colin S CooperNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.
Robert G BristowManchester Cancer Research Centre and Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-8553-9544
David C WedgeManchester Cancer Research Centre and Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-7572-3196
Thorsten SchlommDepartment of Urology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-9557-4653
Geoff MacintyreSpanish National Cancer Research Centre (CNIO), Madrid, Spain. gmacintyre@cnio.es.ORCID http://orcid.org/0000-0003-3906-467X
Jüri ReimandComputational Biology Program, Ontario Institute for Cancer Research (OICR), Toronto, Ontario, Canada. juri.reimand@utoronto.ca.ORCID http://orcid.org/0000-0002-2299-2309
Joachim WeischenfeldtBiotech Research & Innovation Centre (BRIC) - University of Copenhagen, Copenhagen, Denmark. joachim.weischenfeldt@bric.ku.dk.ORCID http://orcid.org/0000-0002-3917-5524
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer follows a long and heterogeneous disease course with incompletely understood aetiology
Identifiers
PMID
42717097What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.